SuperNK is a patented immunotherapy
With a culturing technology that mass produces 95% pure NK cells
with superior killing ability.
(Patented in the US, China and Korea and international PCT application in many countries)
Existing NK cell culture technologies mainly use highly concentrated cytokines, which only increase the number of NK cells (proliferation). SuperNK’s novel cell culture technology uses cytotoxicity enhancing agents and proliferating agents that the result is both highly cytotoxic and a large number of NK cells.
SuperNK® has unique patented NK cell culture technology.
Existing NK cell culture technology
Novel NK cell culture technology
NK cells can be multiplied by 1,000 to 10,000 folds through a patented culturing technology.
Change in the Number of NK Cells during the culture
The purity of NK cells is increased to 95% through NKMAX’s culturing process.
Comparison of NK Cell Purity before & after Culturing
The culturing process reinforces the ability to kill cancer cells.
Comparison of Cancer Cell killing ability before & after Culturing
Effector cell(Super NK):Target cell(K562 cell line) ratio = 1:1
The culturing process reinforces immune function.
Comparison of Cytokine Secretion before & after Culturing
The novel potential immunotherapy that overcomes the limitations of the existing NK cell therapy
|Limitation of existing NK cell therapies||Superiority of SuperNK®|
|Generally display decreased killing ability||
|Lower NK cell purity containing a large portion of other immune cells||
|Difficult in vitro mass production||
|Ineffective treatment due to inhibition of Immune function in cancer patients||
SuperNK® 100mL (1 bag), 2-6 billion NK cells intravenous injection